Nacuity Pharmaceuticals Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $12.9M

  • Investors
  • 5

Nacuity Pharmaceuticals General Information

Description

Operator of a biotechnology company intended to offer treatments for retinitis pigmentosa and other ophthalmological disorders. The company offers drug candidates focused on treating ocular oxidative stress and other ocular diseases, enabling healthcare professionals to help and treat patients suffering from such disorders.

Contact Information

Website
www.nacuity.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 306 West 7th Street
  • Suite 310
  • Fort Worth, TX 76102
  • United States
+1 (817)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 306 West 7th Street
  • Suite 310
  • Fort Worth, TX 76102
  • United States
+1 (817)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nacuity Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 29-Dec-2025 $12.9M Completed Clinical Trials - Phase 3
4. Accelerator/Incubator Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 15-Jun-2022 Completed Clinical Trials - Phase 2
2. Accelerator/Incubator $11.2M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 20-Jul-2017 $11.2M $11.2M Completed Pre-Clinical Trials
To view Nacuity Pharmaceuticals’s complete valuation and funding history, request access »

Nacuity Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Nacuity Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Nacuity Pharmaceuticals Patents

  • 145

    Total Documents Applications and Grants

  • Total Patents Families

  • 75

    Granted

  • 40

    Pending

  • Expiring in next 12 mo

Nacuity Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260240778-A1 Method for preparation of n-acetyl cysteine amide, derivatives and tablets thereof, and their pharmacokinetics Pending 08-Apr-2025
WO-2026217645-A1 Method for preparation of n-acetyl cysteine amide, derivatives and tablets thereof, and their pharmacokinetics Pending 08-Apr-2025
WO-2026177993-A1 Preparation of n-acetyl cysteine amide and derivatives thereof Pending 18-Feb-2025
WO-2026165469-A1 Method for preparation of n-acetyl cysteine amide and derivatives thereof Pending 03-Feb-2025
WO-2026072694-A1 N-acetylcysteine amide inhibits reduction in vision in patients with usher syndrome associated retinitis pigmentosa Pending 25-Sep-2024 A61K31/16
To view Nacuity Pharmaceuticals’s complete patent history, request access »

Nacuity Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nacuity Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Foundation Fighting Blindness-National Neurovision Research Institute Not-For-Profit Venture Capital Minority
Retinal Degeneration Fund Not-For-Profit Venture Capital Minority
Tarnagulla Ventures Venture Capital Minority
HSC Next Accelerator/Incubator
Johns Hopkins Technology Ventures Accelerator/Incubator
To view Nacuity Pharmaceuticals’s complete investors history, request access »

Ready to get started?

Request a free trial

Nacuity Pharmaceuticals FAQs

  • When was Nacuity Pharmaceuticals founded?

    Nacuity Pharmaceuticals was founded in 2017.

  • Where is Nacuity Pharmaceuticals headquartered?

    Nacuity Pharmaceuticals is headquartered in Fort Worth, TX.

  • What is the size of Nacuity Pharmaceuticals?

    Nacuity Pharmaceuticals has 6 total employees.

  • What industry is Nacuity Pharmaceuticals in?

    Nacuity Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Nacuity Pharmaceuticals a private or public company?

    Nacuity Pharmaceuticals is a Private company.

  • What is Nacuity Pharmaceuticals’s current revenue?

    The current revenue for Nacuity Pharmaceuticals is .

  • How much funding has Nacuity Pharmaceuticals raised over time?

    Nacuity Pharmaceuticals has raised $40.6M.

  • Who are Nacuity Pharmaceuticals’s investors?

    Foundation Fighting Blindness-National Neurovision Research Institute, Retinal Degeneration Fund, Tarnagulla Ventures, HSC Next, and Johns Hopkins Technology Ventures have invested in Nacuity Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process